By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    stress disorder
    5 Ways To Manage Post-Traumatic Stress Disorder
    October 27, 2021
    Medical device classification and development strategies
    Medical device classification and development strategies
    April 5, 2023
    varicose veins
    Varicose Veins Prevention: 3 Lifestyle Changes to Make Right Now
    May 1, 2022
    Latest News
    Getting Back in the Game: Sports Injuries Rehabilitation Tips
    May 31, 2023
    4 Signs It’s Time to See a Therapist
    May 24, 2023
    11 Ways To Modernize Your Private Practice
    May 17, 2023
    How to Recognize the Signs of Hormonal Imbalance in Men
    May 29, 2023
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    Mobile Health Around the Globe: Bonus Video! An Overview of Mobile Innovations
    May 20, 2013
    ACA education
    What Americans Don’t Know About the Affordable Care Act
    April 5, 2018
    Screen Shot 2014-04-15 at 7.27.04 AM
    The Aesthetics and Reconstructive Surgery Products Global Market
    April 16, 2014
    Latest News
    MRI Sedation Options: What You Should Know Before Screening
    May 17, 2023
    What is the Process of Creating Medicine from Nature?
    May 2, 2023
    Choosing the Right Treatment Option for Varicose Veins
    May 2, 2023
    What Are Wrong-Site Surgeries and How Do They Occur?
    April 27, 2023
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: BioPharma Beat: We Want Healthcare at Any Price – Until We Have It
Share
Sign In
Notification Show More
Aa
Health Works CollectiveHealth Works Collective
Aa
Search
Have an existing account? Sign In
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Finance > BioPharma Beat: We Want Healthcare at Any Price – Until We Have It
BusinessFinanceHealth ReformMedical EthicsMedical InnovationsPublic Health

BioPharma Beat: We Want Healthcare at Any Price – Until We Have It

David Davidovic
Last updated: 2014/05/07 at 8:00 AM
David Davidovic
Share
6 Min Read
biopharma beat
SHARE

biopharma beatWe all know the expression, “We often don’t appreciate things until they are gone.”  There is a corollary: “We often appreciate things more before we get them than once we have them.”

biopharma beatWe all know the expression, “We often don’t appreciate things until they are gone.”  There is a corollary: “We often appreciate things more before we get them than once we have them.”

Surely there is ample academic research in this area.  Academic concepts such as “Cognitive Dissonance” and “Transactional Involvement” come to mind and seem to apply; however, I will base this article on personal observations and years of experience working in healthcare.

The first time I observed this phenomenon was after the launch of Merck’s Crixivan for HIV in 1996. Recall that at the time, the AIDS epidemic was front-page news with thousands of people afflicted and with many suffering and dying. There were loud cries for more research; cries calling for the accelerated development of new drugs; cries for solutions at virtually any price…and money was no object!

More Read

virtual reality in optometry

Virtual Reality Visual Field Test Device in Healthcare

Best Practices for Healthcare Call Centers Should Follow in 2023
How Hospitals and Other Healthcare Providers Can Boost Employee Morale
What are the Benefits of Hospitals and Clinics Using Expense Management Services?
Using EHR systems in healthcare for Cost-Effective Services

Crixivan was developed at a cost of over $1 billion, resulting in the most powerful anti-retroviral at the time, with excellent properties to bring down viral loads and to improve not only disease state and quality of life, but also morbidity and mortality.  This product helped change what was essentially a terminal illness into a chronic one that could be managed.

At launch, Crixivan was priced around $12 per day, justified in part by the costly research and huge capital-intensive manufacturing plants that had to be built just for this product (taken in grams not milligrams, so the need was for tons of ingredient materials not pounds or kilos).  But, once the product was approved and priced, many quickly forgot that there had been nothing available before and that people had been willing to pay a lot for something, anything, to help and bring hope in this area.  They conferred a very high value-for-money on a potential solution.  Soon after the product became available, people’s perceptions suddenly turned around and the predominant feeling became that the drug was too expensive, changing the perceived-value equation.

It is an interesting dynamic that can be observed in many aspects of daily living.  In healthcare, we’ve seen it with heart disease where great science has led to the development of statins and new classes of anti-hypertensives and anti-platelet agents, all leading to dramatic improvements in morbidity and mortality from heart disease – the number one killer.  Yet, there are many complaints that a couple of dollars a day is too much to pay for this benefit. 

A similar experience has been seen with Genentech’s Herceptin for breast cancer and more recently with Gilead’s Sovaldi for hepatitis C.  For a long time, hepatitis has been treated with old interferon-based agents which are extremely difficult to tolerate and are moderately effective.  Few patients elected to be treated or did not complete treatment, so overall success and outcomes improvements have been limited — and still expensive, though arguably not as costly as if all eligible patients were successfully treated.  Then new drugs like Vitrelis and Incivek, with a lower incidence of side effects resulted in better success rates.  

More recently, Sovaldi demonstrated to be more effective, to allow for a shorter course of therapy, and to be better tolerated…but definitely much more expensive for each patient treated.  The argument that supporters of this product make is that it may be more expensive on a per-patient basis, but the benefits are such that, overall, makes it a better value.  The costs of this untreated or poorly-treated disease are staggering – not only in economic terms but also in all the ways serious diseases affect quality of life, and more.  What is scaring payers most is not necessarily the cost of the product for a single patient, but the likely total cost across all of their patients because 1) the disease is highly prevalent, and 2) with these advances more people will actually get treated and will actually stay on treatment, thus driving the overall cost.  But then the disease will be managed, with ensuing benefits.

The purpose of this article is not to support or justify high prices of medicines or any similar agenda.  It is simply to highlight that pricing of drugs and their resulting cost is not a straightforward calculation and is not simply a matter of facts and figures; there is this curious phenomenon around perceived value that we tend to desperately want and need solutions to serious problems, at any price, and then when we get them, they are too expensive – also at any price. 

For a discussion on The Price, The Cost and The Value of Pharmaceutical Care, refer to an earlier article on this site: http://healthworkscollective.com/david-davidovic/128056/bio-pharmaceutical-care-price-cost-and-value 

Is it a philosophical, psychological, social or economic discussion?  Or all of the above? 

TAGGED: behavioral economics, BioPharma Beat, cost-effectiveness, healthcare pricing, healthcare value, hepatitis, pharma, Price

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
David Davidovic May 7, 2014
Share this Article
Facebook Twitter Copy Link Print
Share
Previous Article healthcare delivery in America The Paradox in American Healthcare
Next Article IPPS Regulations 5 Aspects of CMS’s 2015 Proposed IPPS Regulations

Stay Connected

1.5k Followers Like
4.5k Followers Follow
2.8k Followers Pin
136k Subscribers Subscribe

Latest News

medical bills
Who is Responsible for Paying the Medical Bills After an Injury?
News June 1, 2023
sports injury rehabilitation
Getting Back in the Game: Sports Injuries Rehabilitation Tips
Health May 31, 2023
brush your day
How Many Times A Day Should You Brush Your Teeth?
Dental health May 29, 2023
Chiropractic Laser Therapy: A Beacon of Hope for Chronic Pain Sufferers
Chiropractic Laser Therapy: A Beacon of Hope for Chronic Pain Sufferers
Therapies May 29, 2023

You Might also Like

Types of Remote Access Solutions for Hospitals
Medicare

Types of Remote Access Solutions for Hospitals

April 27, 2023
medical interpreters
Medical Innovations

The Vital Role of Medical Interpreting Services In Healthcare

April 21, 2023
get a career in medical device sales
Medicare

What Are the Benefits of Attending Medical Sales College?

April 10, 2023
subscription based telemedicine
Hospital Administration

Subscription Management Solutions Are Crucial for Telemedicine

April 5, 2023
//

We influence million of users and is the most authentic source of information on healthcare business and technology news.

Quick Links

  • About
  • Contact
  • Privacy
Subscribe

Subscribe to our newsletter to get our newest articles instantly!

Follow US

© 2008-2023 HealthWorks Collective. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?